Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dasatinib
Drug ID BADD_D00589
Description Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
Indications and Usage For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
Marketing Status approved; investigational
ATC Code L01EA02
DrugBank ID DB01254
KEGG ID D03658; D06414
MeSH ID D000069439
PubChem ID 3062316
TTD Drug ID D0E6XR
NDC Product Code 0003-0857; 53104-7725; 0003-0852; 68554-0070; 0003-0528; 59651-468; 54893-0015; 62207-973; 63285-863; 63285-866; 0003-0855; 63285-867; 0003-0527; 14778-1313; 50193-0524; 54893-0047; 63285-862; 0003-0524; 63285-864; 63285-865
UNII RBZ1571X5H
Synonyms Dasatinib | N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | Sprycel | (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | BMS 354825 | 354825, BMS | BMS354825 | BMS-354825
Chemical Information
Molecular Formula C22H26ClN7O2S
CAS Registry Number 302962-49-8
SMILES CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Platelet dysfunction01.08.03.0030.000302%Not Available
Epidural haemorrhage12.01.10.013; 24.07.04.017; 17.08.05.004--Not Available
Autoimmune haemolytic anaemia10.04.01.005; 01.06.01.0040.000224%Not Available
Sinus node dysfunction02.03.03.0170.000168%
Bladder transitional cell carcinoma20.03.04.003; 16.08.01.0020.000112%Not Available
Blast cell proliferation16.21.03.007; 01.13.03.0070.000694%Not Available
Blood blister23.03.01.028; 12.01.06.0130.000246%Not Available
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.0020.000112%Not Available
Large granular lymphocytosis16.01.11.001; 01.10.11.0010.001567%Not Available
Malignant pleural effusion22.05.04.001; 16.32.03.0140.000112%Not Available
Normal newborn18.08.06.0010.001254%Not Available
Recurrent cancer16.16.01.0150.000168%Not Available
Teeth brittle07.09.05.0150.000246%Not Available
Testicular cyst21.13.02.005; 16.36.02.0030.000381%Not Available
Neck mass15.03.02.0070.000246%Not Available
Live birth18.08.02.0070.000985%Not Available
Blast crisis in myelogenous leukaemia01.10.08.002; 16.01.08.0020.000448%Not Available
Peripheral artery occlusion24.04.03.0220.000224%Not Available
Gastrointestinal oedema07.11.01.0120.000168%Not Available
Colitis erosive07.08.01.0180.000112%Not Available
Leukaemia recurrent16.01.03.005; 01.10.03.0050.000638%Not Available
Acute lymphocytic leukaemia recurrent16.01.01.003; 01.10.01.0030.001231%Not Available
Graft versus host disease in skin12.02.09.031; 10.02.01.062; 23.07.04.0250.000224%Not Available
Graft versus host disease in liver12.02.09.029; 10.02.01.060; 09.01.07.0330.000168%Not Available
Central nervous system leukaemia17.02.10.019; 16.01.03.004; 01.10.03.0040.000112%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000224%Not Available
Chronic myeloid leukaemia transformation16.01.07.004; 01.10.07.0040.000392%Not Available
Foetal hypokinesia18.03.02.0150.000112%Not Available
Chronic myeloid leukaemia recurrent16.01.07.003; 01.10.07.0030.000168%Not Available
Graft versus host disease in gastrointestinal tract12.02.09.028; 10.02.01.059; 07.11.01.0270.000224%Not Available
The 21th Page    First    Pre   21 22    Next   Last    Total 22 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene